SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~March~~April, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

FOR                             Once-Daily IMMEDIATEREQUIP™ RELEASE                                            26LP MARCHExtended-Release 2007Tablets Approved in France


                              SkyePharmaLONDON,  UK,  Monday,  April 23, 2007 - SkyePharma  PLC (LSE:SKP;  NASDAQ:  SKYE) today  announces  that  regulatory  approval has been
                         Votingreceived Rightsin France for ropinirole  prolonged  release  tablets (which will be marketed as REQUIP™ LP (1) in France).  The new prolonged
release  tablet of  ropinirole  is taken once daily,  and Capitalis indicated for the  treatment of  Parkinson's  disease  (PD).  SkyePharma's
partner for the product,  GlaxoSmithKline has also received approval in Slovakia,  Slovenia,  Latvia,  Estonia and Canada, and plans to
gain further marketing authorisations in other countries.
In
On conformity13 withApril,  SkyePharma  announced that the TransparencyUnited Directive,States weFood herebyand notifyDrug  Administration had accepted for filing the application by GSK
for  approval to market the product in the US.  REQUIP™ LP has been  designed  to provide a steady  rate of
  absorption  in the following:body to
help reduce blood plasma fluctuations over 24 hours.

ConsequentFrank toCondella,  CEO theof admissionSkyePharma,  commented:  "We are pleased to tradingannounce the French  approval of 61REQUIP™ LP,224,490 newa Ordinarysignificant  step Sharesin
the roll-out of  ropinirole  prolonged  release  tablets  across 10pthe  Continent.  In the coming  months,  we expect to gain  additional
eachEuropean whichapprovals tookand placewill continue the roll-out of this morning,important product across other member states of the European Union."

For further information please contact:

SkyePharma PLC                                        Frank Condella               +44 20 7491 1777
                                                      Ken Cunningham
                                                      Peter Grant

Financial Dynamics (UK Enquiries)                     David Yates                  +44 20 7831 3113
                                                      Deborah Scott

Trout Group (US Enquiries)                            Christine Labaree            +1 617 583 1308
                                                      Seth Lewis


NOTES TO EDITORS

About Ropinirole
Ropinirole is a non-ergot dopamine agonist currently marketed as REQUIP®  (ropinirole HCl) Tablets, an  immediate-release  formulation.
It has an  indication in the U.S. for the treatment of the signs and symptoms of  idiopathic  Parkinson's  disease issuedand shareis  administered
three capitaltimes a day. REQUIP™ LP uses  SkyePharma's  proprietary  GeomatrixTM  technology and has been designed to be given once daily and
consiststo have a simpler and faster titration schedule.

Our partner GSK conducted two pivotal studies to support of 814the  registration of ropinirole  prolonged  release tablets in Europe.  One
study was a ropinirole  monotherapy  study in early PD,988,636 Ordinaryand Sharesthe other was an adjunct study with votinglevodopa rights(L-dopa) in advanced PD. These
studies confirmed the efficacy of ropinirole  Noprolonged sharesrelease aretablets,  in heldterms of symptomatic control to allow patients to continue
intheir treasurydaily activities.

About Parkinson's Disease
Parkinson's  Thereforedisease is a chronic,  progressive  and  debilitating  neurological  condition that impairs the totalbody's numberability ofto votingmove rightsand
balance.  Researchers have determined that Parkinson's  disease involves  pathways in the Companybrain  responsible isfor motor control that are
814functioning  improperly.  Patients  with  Parkinson's  disease  experience a reduction  in  dopamine,988  a key chemical in the brain that
communicates  messages about  movement,636  resulting in the symptoms of  Parkinson's  disease.  These  symptoms may include  bradykinesia
(slower-than-normal  voluntary movements),  rigidity  (stiffness),  tremor (involuntary shaking) and postural instability (trouble with
balance).
The
In aboveEurope,  an figureestimated  800,000 (814people live with PD,988 with about 75,636000 new cases diagnosed  every year.(i) mayThe becorrect  medication usedis
key byto shareholdershelping asthem themaintain denominator
fora thegood calculationsquality byof whichlife theyand  minimising  long-term  side caneffects.  As determinewith ifmany  diseases,  compliance theyis area
significant requiredbarrier to notify
theirpositive interestpatient outcomes in PD.

About SkyePharma PLC
Using its  proprietary  drug delivery  technologies,  SkyePharma  develops ornew  formulations  of known  molecules to provide a changeclinical
advantage inand theirlife-cycle  extension.  The interestCompany has ten approved products in the areas of oral,  inhalation SkyePharmaand PLCtopical underdelivery that
are marketed throughout the world by leading pharmaceutical companies.
FSAFor more information, visit www.skyepharma.com

About GlaxoSmithKline
GlaxoSmithKline,  with U.S.  operations in Philadelphia and Research Triangle Park, N.C., is one of the world's Disclosureleading  research-based
pharmaceutical and Transparencyhealth Rulescare companies.


1.   In the other member states of the European Union, the product suffixes under  consideration  are  REQUIP-MODUTAB™,  REQUIP™ XL, or
     REQUIP DEPOT™.  REQUIP, MODUTAB AND DEPOT are trademarks of the GlaxoSmithKline group of companies.

i    European     Federation     of     Pharmaceutical     Industries     and     Associations:     Disease     Burden    in    Europe.
     http://www.efpia.org/Content/Default.asp?PageID=133 (Accessed April 2007).


END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ John Murphy

                                                                       Name: John Murphy
                                                                          Title: Company Secretary

Date: ~~March~~April 2623, 2007

Filing Compare · SKYEPHARMA PLC